Antibody-Drug Conjugates

NextCure Partners with Simcere for Novel ADC in $745M Deal

4 weeks ago talkbio0Tagged ADC, Antibody-Drug Conjugates, CDH6 gene, cellular targeting, NextCure, SIM0505, Simcere, therapeutic autologous dendritic cells

NextCure; Simcere; Antibody-Drug Conjugate; ADC; SIM0505; CDH6 Targeting

ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

4 weeks ago talkbio0Tagged Antibody-Drug Conjugates, facility closure, layoffs, preclinical programs, R&D, restructuring, Solid Neoplasm, therapeutic autologous dendritic cells, UK, Zynlonta

ADC Therapeutics; layoffs; UK facility closure; biotech restructuring; R&D; antibody-drug conjugates; solid tumors; Zynlonta; preclinical programs

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

1 month ago talkbio0Tagged Antibody-Drug Conjugates, Combined Modality Therapy, Gilead Sciences, Immunotherapy, Keytruda, Phase 3 trial, practice-changing, Progression-Free Survival, TNBC, Triple Negative Breast Neoplasms, Trodelvy

Gilead Sciences; Trodelvy; Keytruda; triple-negative breast cancer; TNBC; antibody-drug conjugate; immunotherapy; progression-free survival; ASCO 2025; phase 3 trial; practice-changing; combination therapy

Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences

1 month ago talkbio0Tagged Antibody-Drug Conjugates, Astellas, Evopoint Biosciences, Licensing Deal, Neoplasms, therapeutic autologous dendritic cells

Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011

Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC

2 months ago talkbio0Tagged 55%, Antibody-Drug Conjugates, Emi-Le, emiltatug ledadotin, Malignant neoplasm of breast, Mersana, VTCN1 gene

Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%

Lotte Bio launches ADC services; Ypsomed to focus on self-injection business

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Biological Factors, Lotte, Manufacture, self-injection business, Services, Ypsomed

Antibody-Drug Conjugates, Lotte, Ypsomed, Services, Biological Factors, Manufacture, self-injection business

AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer

3 months ago talkbio0Tagged Antibodies, Antibody-Drug Conjugates, AstraZeneca, Daiichi, deruxtecan-nxki, Enhertu, fam-trastuzumab, first-line therapy, HER2-positive metastatic breast cancer, pertuzumab, Progression-Free Survival, Sankyo

Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab